Company Filing History:
Years Active: 2015
Title: The Innovative Mind of Sam Schlageck
Introduction
Sam Schlageck is a notable inventor based in Kansas City, MO, whose contributions to medical technology have significantly impacted the analysis of biological fluids. His dedication to innovation in the field of chromatography has led to the development of a patented high-speed, automated chromatographic analyzer that enhances the determination of both nonglycated and glycated proteinaceous species in blood samples.
Latest Patents
Sam holds one patent titled "High-speed, automated chromatographic analyzer for determination of nonglycated and glycated proteinaceous species in blood samples." This invention introduces high-speed, automated analyzers designed for the efficient analysis of biological fluids, like whole blood or blood-derived components. The specialized analyzer and sample transfer features enable remarkably fast injection-to-injection analysis times of approximately one minute, particularly crafted for HPLC analysis of glycated and nonglycated proteinaceous species present in blood samples.
Career Highlights
Currently, Sam is associated with Trinity Biotech, Primus Corporation, where he utilizes his innovative expertise to further advancements in diagnostic technology. His role demonstrates his commitment to improving the effectiveness of medical testing and patient care through engineering advancements.
Collaborations
Throughout his career, Sam has had the opportunity to collaborate with notable colleagues, including Jon Davis and Roger L Donley. These collaborations have allowed for a fruitful exchange of ideas and have contributed to the development of cutting-edge solutions in the field.
Conclusion
In conclusion, Sam Schlageck is a distinguished inventor whose work in developing high-speed automated testing technologies marks a significant milestone in the biomedical field. His dedication to innovation continues to influence the way that blood samples are analyzed, ultimately enhancing healthcare outcomes.